

Kidney Cancer Assessment and Therapeutics Pipeline Review H2 2017

Kidney Cancer Therapeutic and Disease Pipeline Review H2

PUNE, INDIA, January 3, 2018 /EINPresswire.com/ -- Summary

[Kidney cancer](#) also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2659610-kidney-cancer-renal-cell-cancer-pipeline-review-h2-2017> □

Companies mentioned

4SC AG

Aadi Bioscience Inc

AbbVie Inc

Actuate Therapeutics Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Advenchen Laboratories LL

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Show more...

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development

for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 15, 94, 88, 5, 78, 12 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 13, 6 and 13 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective

counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points

Table of Contents 2

Introduction 8

Kidney Cancer (Renal Cell Cancer) - Overview 9

Kidney Cancer (Renal Cell Cancer) - Therapeutics Development 10

Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 49

Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 73

Kidney Cancer (Renal Cell Cancer) - Drug Profiles 152

Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1368

Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1383

Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1387

...Continued□

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/2659610-kidney-cancer-renal-cell-cancer-pipeline-review-h2-2017> □

Get in touch:□

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/424551732>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.